Case Report: Successful treatment of pediatric alopecia universalis with ritlecitinib after failure of baricitinib
Alopecia areata is characterized by difficult treatment and easy recurrence, especially posing significant physical and psychological distress to children. However, current treatment options for Pediatric alopecia areata are relatively limited, with generally poor efficacy and numerous side effects. We report the first case of a Pediatric patient transitioning from baricitinib therapy to ritlecitinib, resulting in favorable clinical outcomes. We believe that the result represent a meaningful advance in our understanding of how to treat children with chronic severe AA and feel that this would be of substantial interest to the broad readership of Frontiers in medicine.
Authors
- Xiaoqing Lv (ORCID: https://orcid.org/0000-0002-8681-1271)
- Jing Mao (ORCID: https://orcid.org/0009-0001-8796-2311)
- Chao Ji (ORCID: https://orcid.org/0000-0002-1913-9702)
- Shi‐Fan Ruan
- Ying Chen (ORCID: https://orcid.org/0009-0005-8351-6620)
- Lihong Chen (ORCID: https://orcid.org/0000-0003-2385-4466)
- Qiuyun Xu
- Bo Cheng (ORCID: https://orcid.org/0000-0001-9551-1142)
- Wenjie Xia (ORCID: https://orcid.org/0000-0003-3091-0032)
- Zheyu Zhuang
- Siyi Bao
- Li Zhu (ORCID: https://orcid.org/0009-0003-7557-2417)
Institutions
- Fujian Medical University (CN)
- Capital Medical University (CN)
- First Affiliated Hospital of Fujian Medical University (CN)
- Fujian Provincial Hospital (CN)
- Nanchong Central Hospital (CN)
- Fuzhou University (CN)
Publication Details
- Journal
- Frontiers in Medicine
- Published
- 2025-12-18
- DOI
- https://doi.org/10.3389/fmed.2025.1675062
- Primary Topic
- Hair Growth and Disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China